WASHINGTON (AP) - U.S. health officials on Wednesday approved the first pill made from healthy bacteria found in human waste to fight dangerous gut infections - an easier way of performing so-called fecal transplants.

The new treatment from Seres Therapeutics provides a simpler, rigorously tested version of stool-based procedures that some medical specialists have used for more than a decade to help patients.

The Food and Drug Administration cleared the capsules for adults 18 and older who face risks from repeat infections with Clostridium difficile, a bacteria that can cause severe nausea, cramping and diarrhea.

C. diff is particularly dangerous when it reoccurs, leading to between 15,000 and 30,000 deaths per year. It can be killed with antibiotics but they also destroy good bacteria that live in the gut, leaving it more susceptible to future infections. The new capsules are approved for patients who have already received antibiotic treatment.

More than 10 years ago, some doctors began reporting success with fecal transplants - using stool from a healthy donor - to restore the gut’s healthy balance and prevent reinfections.

The FDA approved the first pharmaceutical-grade version of the treatment last year from a rival drugmaker, Ferring Pharmaceuticals. But that company’s product - like most of the original procedures - must be delivered via the rectum.

Cambridge Massachusetts-based Seres will market its drug as a less invasive option. The treatment will be sold under the brand name Vowst and comes as a regimen of four daily capsules taken for three consecutive days. Both of the recent FDA approvals are the product of years of pharmaceutical industry research into the microbiome, the community of bacteria, viruses and fungi that live in the gut.

Currently most fecal transplants are provided by a network of stool banks that have popped up at medical institutions and hospitals across the country.